Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-03-25
2008-03-25
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S005000, C435S235100
Reexamination Certificate
active
07348014
ABSTRACT:
The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
REFERENCES:
patent: 5518888 (1996-05-01), Waldman
patent: 6884786 (2005-04-01), Kieny et al.
patent: WO 92/06180 (1992-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/27643 (1994-12-01), None
patent: WO 99/03885 (1999-01-01), None
patent: WO 00/09730 (2000-02-01), None
Vazquez et al. Journal of Virology, 1999, vol. 73, p. 9098-9109.
Antoine et al. Virology, 1998, vol. 244, p. 365-396.
Barker et al. Science, 2001, vol. 294, p. 1-7.
Attwood, Science, 2000, vol. 290, p. 1-6.
Balloul et al. Cell and Molec. Biology, vol. 40, p. 49-59.
Galmiche et al., “Expression of a functional single chain antibody on the surface . . . tumour cell targeting”, Journal of General Virology, 1997, pp. 3019-3027, vol. 78, Great Britain.
Russel et al., “Retroviral vectors displaying functional antibodu fragments”, Oxford University Press, 1993, pp. 1081-1085, vol. 21, No. 5, United Kingdom.
Bernard Moss, “Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety”, Colloquium Paper, 1996, pp. 11341-11348, vol. 93, USA.
Paul, S. “Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody” 2000 Cancer Gene Ther. (2000) 7, pp. 615-623.
Hsiao, J.C. “Cell Surface Proteoglycans Are Necessary for A27L Protein-Mediated cell Fusion: Identification of the N-tmerinal Region of A27L Protein as the Glycoaminoglycan-Binding Domain” Journ. Of Virol. (Oct. 1998) 72, pp. 8374-8379.
Urbanski et al., “Internalization of E. coli ST mediated by guanylyl cyclase c in T84 human colon carcinoma cells,” Biochimica et Biophysica Acta, 1245, pp. 25-36, Elsevier Science B.V. 1995.
Rodriguez et al., “Mapping and Nucleotide Sequence of the Vaccinia Virus Gene That Encodes a 14-Kilodalton Fusion Protein,” Journal of Virology, 61(11) pp. 3550-3554, American Society for Microbiology, 1987.
Kain et al., “Molecular Cloning and Expression of a Novel Human trans-Golgi Network Glycoprotein, TGN51, That Contains Multiple Tyrosine-containing Motifs” The Journal of Biological Chemistry, 273(2), pp. 981-988, The American Society for Biochemistry and Molecular Biology, Inc., 1998.
Lin et al., “Structural Analysis of the Extracellular Domain of Vaccinia Virus Envelope Protein, A27L, by NMR and CD Spectroscopy,” The Journal of Biological Chemistry, 277(23), pp. 20949-20959, The American Society for Biochemisty and Molecular Biology, Inc., 2002.
Carrithers et al. “Guanylyl cyclase C is selective marker for metastatic colorectal tumors in human extraintestinal tissues,” Proc. Natl. Acad. Sci., 93, pp. 14827-14832, Medical Sciences, 1996.
Vázquez et al., “Identification of Functional Domains in the 14-kilodalton Envelope Protein(A27L)of Vaccinia Virus,” Journal of Virology, 73(11), pp. 9098-9109, American Society for Microbiology, 1999.
Chung et al., “A27L Protein Mediates Vaccinia Virus Interaction with Cell Surface Heparan Sulfate,” Journal of Virology, 72(2), pp. 1577-1585, American Society for Microbiology, 1998.
Vázquez et al., “The Vaccinia Virus 14-Kilodalton(A27L)Fusion Protein Forms a Triple Coiled-Coil Structure and Interacts with the 21-Kilodalton(A17L)Virus Membrane Protein through a C-Terminal α-Helix,” Journal of Virology, 72(12), pp. 10126-10137, American Society for Microbiology, 1998.
Vanderplasschen et al., “Intracellular and extracellular vaccinia virions enter cells by different mechanisms,” Journal of General Virology, 79, pp. 877-887, 1998.
Galmiche et al., “Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting,” Journal of General Virology, 78, pp. 3019-3027, 1997.
Hsiao et al., “Vaccinia virus Envelope D8L Protein Binds to Cell Surface Chondroitin Sulfate and Mediates the Adsorption of Intracellular Mature Virions to Cells,” Journal of Virology, 73(10), pp. 8750-8761, American Society for Microbiology, 1999.
Balloul Jean Marc
Erbs Philippe
Geist Michel
Paul Stephane
Silvestre Nathalle
Boesen Agnieszka
Buchanan & Ingersoll & Rooney PC
Campell Bruce R.
Transgene S.A.
LandOfFree
Poxvirus with targeted infection specificity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Poxvirus with targeted infection specificity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Poxvirus with targeted infection specificity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799080